Praetego develops novel drugs to protect patients from the chronic diseases of aging. Our primary goal is to develop a patient-centric therapeutic (oral, cost effective, and well tolerated) able to deter neurodegeneration. Through this endeavor, we seek to alter the trajectory of AD and to improve the experience of aging. Praetego (from Latin, meaning to protect) is a female founded and led company located in Durham, North Carolina. Founded in 2017, the management team are industry veterans and disease specialists; many of whom worked together in previous roles to develop candidates for diseases associated with aging. Praetego is developing potent neuroprotective therapeutics with demonstrated potential for the treatment of Alzheimer’s disease (AD). The Amadorins are potent small molecules uniquely targeting an initial step in a damaging cascade (the Maillard reaction) by preventing the oxidation of glycated proteins in the central nervous system. By preventing this step, the Amadorins inhibit a bolus of pathogenic by-products driving neurodegeneration. Specifically, the mechanism inhibits the production of reactive oxygen species (ROS), free radicals, and cross-linking driven by dicarbonyls - all highly reactive mediators of neuronal damage. By acting upstream on these processes, Amadorins effectively limit downstream pathogenic mechanisms leading to neurodegeneration. The lead asset, PTG-630, is initiating IND-enabling studies with the goal of launching a clinical development program to treat Alzheimer’s disease in 2024. Praetego has raised $7M since its founding, most of which is non-dilutive. Praetego has received 5 NIH awards from three unique institutions – NIDDK, NIA, and NEI to further the Amadorin candidates. The current Amadorins were developed in house and covered by multiple issued and pending patents.